Bear Sterns Health Innoventures
Former Roche and BASF/Knoll execs are founding partners in Bears Sterns venture capital fund Health Innoventures. Former Roche research execs Jurgen Drews, Fritz Buhler and Stefan Ryser and former Knoll VP-Business Development Elizabeth Czerepak are partners in the fund, which will invest in early- to mid-stage biotech and information technology companies. The fund has $212 mil. in committed capital
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth